One is that the development of DPP-4 inhibition is a rational drug design based in scientific studies on pathophysiology of type 2 diabetes and that the development shows that it is important to target both the impaired insulin secretion and the high glucagon. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.